Chen et al. showed that the transient overexpression of SUCLG1, PCK2, and GLDC can inhibit the progression of renal cancer cells [38], suggesting that a similar therapeutic approach might prove valuable also in HCC and/or CC preclinical models. The gene discussed is GLDC; the disease is hepatocellular carcinoma.